IN THE NEWS
Cardiac Science Appoints Todd Alberstone as General Counsel
PRNewswire via COMTEX News Network
BOTHELL, Wash. -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices that connect to electronic medical record (EMR) and hospital information systems, appointed Todd Alberstone as vice president and general counsel, effective immediately. In this new role, Mr. Alberstone will report to Dave Marver, president and chief executive officer, and will oversee all of the Company's legal affairs.
"Todd has an outstanding background in technology and intellectual property law," said Dave Marver, Cardiac Science president and chief executive officer. "In addition to helping us be more efficient in our legal spending, Todd will bring strength to our business and the strategic management of our IP portfolio."
Mr. Alberstone, 50, has held positions as director of intellectual property management for the University of Washington, associate general counsel for Real Networks, adjunct professor at Southwestern University School of Law, as well as positions in private practice. Mr. Alberstone has an undergraduate degree in economics from the University of California, Berkeley, and received his J.D. from the University of California, Berkeley (Boalt Hall).
In connection with Mr. Alberstone's hiring, the compensation committee of the Company's board of directors approved an inducement grant made outside of the Company's 2002 Equity Incentive Plan pursuant to which Mr. Alberstone has been awarded, effective as of close of business Jan. 11, 2010, 50,000 restricted common stock units. These restricted stock units vest 25 percent after one year of service and an additional 25 percent after each additional year of service thereafter, until fully vested.
About Cardiac Science
Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT
For more information, contact (media) firstname.lastname@example.org | (investors) email@example.com | +91.80.2852.8088